本维莫德治疗掌跖脓疱病:一项天津地区多中心临床研究  

Benvitimod in the treatment of palmoplantar pustulosis:a multicenter clinical study in Tianjin

作　　者：张帅[1] 王光平 王红梅[3] 李燕[4] 曾三武[2] 闫慧敏 齐放[2] 宋静娜 王斯尧 张池金[1] 张秉新[1] 纪黎明[2] ZHANG Shuai;WANG Guangping;WANG Hongmei;LI Yan;ZENG Sanwu;YAN Huimin;QI Fang;SONG Jingna;WANG Siyao;ZHANG Chijin;ZHANG Bingxin;JI Liming(Department of Dermatology,First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion,Tianjin 300193,China;Department of Dermatology,Tianjin First Central Hospital,Tianjin 300192,China;Department of Dermatology,Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital,Tianjin 300120,China;Department of Dermatology,Tianjin Medical University General Hospital,Tianjin 300052,China)

机构地区：[1]天津中医药大学第一附属医院皮肤科、国家中医针灸临床医学研究中心,天津300193 [2]天津市第一中心医院皮肤科,天津300192 [3]天津市中医药研究院附属医院皮肤科,天津300120 [4]天津医科大学总医院皮肤科,天津300052

出　　处：《临床皮肤科杂志》2024年第4期204-207,共4页Journal of Clinical Dermatology

摘　　要：目的:评价本维莫德在临床研究中治疗掌跖脓疱病的安全性和有效性。方法:选择2021年3月一10月于天津地区多中心应用本维莫德治疗的掌跖脓疱病患者,进行为期8周的治疗及停药后4周的随访,评价患者用药前、后掌跖脓疱病面积和严重程度指数(PPPASI)评分和皮肤病生活质量指数(DLQI)评分,并观察不良反应。结果:治疗8周后,所有患者PPPASI评分与DLQI评分较基线均显著降低,差异均有统计学意义(P<0.05)。治疗8周后,所有患者中痊愈4例、显效4例、有效8例、无效5例,有效率为38.1%。疗程中患者不良反应少且轻微,1例患者出现皮肤肥厚、干燥、脱屑。随访4周,痊愈、显效及有效患者皮损均未复发。结论:本维莫德有望成为治疗掌跖脓疱病的一种有效选择,且不良反应轻微,值得临床进一步研究及应用。Objective:To evaluate the safety and effectiveness of benvitimod in the treatment of palmoplantar pustulosis.Methods:During March 2021 to October 2021,patients with palmoplantar pustulosis treated with benvitimod at multiple hospitals in Tianjin were collected.The treatment lasted 8-week,and its effectiveness was followed up for 1 month by evaluating the PPPASI score and DLQI score before and after treatment and adverse effects.Results:After 8 weeks of treatment,the PPPASI and DLQI score of 21 patients were significantly lower than those at baseline(P<0.05).After 8 weeks of treatment,4 cases were cured,4 cases showed significant effectiveness,8 cases showed effectiveness,and 5 cases showed ineffectiveness.The total clinical effective rate was 38.1%.Adverse reactions were few and mild during the course of treatment,and 1 patient presented thick,dry and desquamation on the skin.After 4 weeks of follow-up,there was no recurrence in the patients showing cure,significant effectiveness and effectiveness.Conclusions:Benvitimod is expected to be an effective choice for the treatment of palmoplantar pustulosis,with slight side effects,and worthy of further clinical research and application.

关 键 词：本维莫德 掌跖脓疱病 银屑病 有效性 安全性 

分 类 号：R753.1[医药卫生—皮肤病学与性病学]